Spontaneously occluded left atrial appendage in a patient with atrial fibrillation and stroke: a case report

Andreas Bugge Tinggaard *, Kasper Korsholm, Jesper Møller Jensen, and Jens Erik Nielsen-Kudsk

Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200 Aarhus N, Denmark

Received 17 September 2019; first decision 22 October 2019; accepted 27 January 2020; online publish-ahead-of-print 27 February 2020

Background

The left atrial appendage (LAA) is the main source of thromboembolism in atrial fibrillation (AF). Transcatheter closure is non-inferior to warfarin therapy in preventing stroke.

Case summary

A patient with two consecutive strokes associated with AF was referred for transcatheter LAA occlusion (LAAO). Preprocedural cardiac CT and transoesophageal echocardiography demonstrated a spontaneously occluded LAA with a smooth left atrial surface, with stationary results at 6- and 12-month imaging follow-up. Warfarin was discontinued, and life-long aspirin instigated.

Discussion

Left atrial appendage occlusion has shown non-inferiority to warfarin for prevention of stroke, cardiovascular death, and all-cause mortality. No benefits from anticoagulation have been demonstrated in patients with embolic stroke of undetermined source. In the present case, we observed that the LAA was occluded and, therefore, treated with aspirin monotherapy assuming similar efficacy as transcatheter LAAO.

Keywords

Atrial fibrillation • Stroke • Left atrial appendage occlusion • Anticoagulation • Case report

Introduction

Atrial fibrillation (AF) is associated with a three- to five-fold increased risk of stroke,¹ and the left atrial appendage (LAA) is known to be the source of thrombi in patients AF. Transcatheter LAA occlusion (LAAO) has shown non-inferiority to warfarin.² Approximately 25% of ischaemic strokes are not associated with recognized cardioembolic sources or carotid atherosclerosis,³ thus, categorized as embolic stroke of undetermined source (ESUS). Anticoagulation therapy has demonstrated no beneficial effects in patients with ESUS.⁴

Notes

* Corresponding author. Tel: +45 30 272 717, Email: andreas.bugge@midt.rm.dk
Handling Editor: Philipp Sommer
Peer-reviewers: Konstantinos Iliodromitis and Ruben Casado Arroyo
Compliance Editor: Stefan Simovic
Supplementary Material Editor: Vishal Shahil Mehta
© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Few cases of absent LAA have previously been described. This case illustrates a spontaneously occluded LAA in a patient with AF and thromboembolic stroke.

**Timeline**

| Index date | Event                                                                 |
|------------|----------------------------------------------------------------------|
| 1 year     | First admission with stroke, patient discharged with dabigatran.      |
| 11 months  | Warfarin was discontinued and life-long aspirin was initiated.        |
| 6 months   | Cardiac CT and TOE show stationary results.                            |
| 5 months   | Cardiac CT and 3D-transoesophageal echocardiography show signs of chronic thrombotic occlusion of the LAA. |
| 1 year and | Repeated CT and TOE show stationary results.                           |
|            | Third CT and TOE again show stationary results.                        |
| 17 days    | Second admission, transient ischaemic attack. Patient changed to warfarin treatment and referred for left atrial appendage (LAA) occlusion. |
|            | Electrocardiogram showed atrial fibrillation and echocardiography a structurally normal heart. All laboratory tests were within normal range. The CHA2DS2-VASc score was 3, and the patient was discharged for elective cardioversion with dabigatran 150 mg twice daily. |
| 17 days    | Warfarin was discontinued and life-long aspirin was initiated.        |

**Case presentation**

A 57-year-old man with a history of well-treated hypertension, hypercholesterolaemia, and prior smoking was hospitalized with symptoms of ischaemic stroke: facial palsy, left-sided neglect, and dysarthria. Complete occlusion of the right internal carotid artery was found by magnetic resonance imaging (MRI). The patient was treated with intra-arterial thrombectomy and thrombolysis. No extra- or intracranial arteriosclerosis or signs of intracerebral small vessel disease was present on MRI. Electrocardiogram showed atrial fibrillation (AF) and echocardiography a structurally normal heart. All laboratory tests were within normal range. The CHA2DS2-VASc score was 3, and the patient was discharged for elective cardioversion with dabigatran 150 mg twice daily.

Symptoms of a transient ischaemic attack (TIA) lead to rehospitalization 17 days later with MRI showing a fresh ischaemic lesion in the right insular cortex. Electrocardiogram showed (persistent) AF. A transoesophageal echocardiography (TOE) excluded intracardiac thrombi and patent foramen ovale. However, the LAA could not be visualized. Dabigatran was substituted with warfarin and the patient was referred for transcatheter LAAO.

A cardiac computed tomography (CT) was performed as preprocedural evaluation for LAAO. Despite optimal acquisition, there was no contrast filling of the LAA. However, the multiplanar reconstructed images revealed the contours of an LAA, with the orifice covered by a smooth surface in continuation of the left atrial wall (Figure 1). A three-dimensional TOE confirmed absence of the LAA with a smooth-walled surface covering the orifice. Based on a multidisciplinary team conference, warfarin therapy was continued. Cardiac CT and TOE were repeated after 6 and 12 months, respectively, with stationary results (Figure 2). After the 12-month scan, warfarin was discontinued, and life-long aspirin, 75 mg daily, was initiated. During treatment with aspirin for 24 months there has been no recurrent stroke or TIA.

**Discussion**

Absence of the LAA is a rare cardiac anomaly, with a presumed congenital aetiology. In contrast to previous reports, we found signs of a remnant LAA defined by the presence of hypo-attenuation and demarcation of the LAA on cardiac CT. These findings could suggest that absence of the LAA, in this case, was caused by chronic thrombotic occlusion. Histological confirmation would have been ideal, but implicitly was not possible. Other imaging modalities, e.g. cardiac MRI, might have provided additional information, however, given the higher spatial resolution of cardiac CT the additional value is uncertain. In addition, thrombophilia screening could have been applied; however, the usefulness of this in stroke patients is unknown, thus, routine testing is not recommended in guidelines. A large study (n = 685) found no association between thrombophilia and stroke, as most prothrombotic conditions increase the risk of venous thrombosis.

The LAA has been identified as the origin of thromboembolism in AF. A recent TOE study of consecutive patients prior to cardioversion of AF or atrial flutter showed thrombosis outside the LAA to be extremely rare, and only present with a simultaneous LAA thrombus. Left atrial appendage occlusion has demonstrated similar or even higher efficacy than warfarin for prevention of ischaemic stroke, cardiovascular death, and all-cause mortality with a concomitant reduction in the rate of major bleedings. Patients undergoing transcatheter LAAO are often treated life-long aspirin therapy. This resembles the secondary preventive strategy of stroke in the absence of AF. In this particular patient, we considered the LAA to be chronically occluded, thereby the source of cardiac embolism in relation to his AF was eliminated. In the absence of lacunar stroke, extra- or intracranial atherosclerosis causing >50% luminal stenosis, and no patent foramen ovale or LAA, we considered the patient to fulfil the criteria of an embolic stroke with undetermined source. The NAVIGATE-ESUS and RESPECT-ESUS trials demonstrated no additional value of rivaroxaban or dabigatran to prevent recurrent stroke as compared to ASA monotherapy. However, the risk of major bleeding was significantly higher with rivaroxaban in NAVIGATE-ESUS and the risk of non-major bleeding was higher with dabigatran in RESPECT-ESUS. Due to a history of intracranial haemorrhage in a closely related family member, the patient was reluctant to anticoagulation therapy. To our knowledge, only one previous case report has addressed the decision of anticoagulation treatment in a patient with (congenital) absent LAA and atrial fibrillation. In that case, the patient had a CHA2DS2-VASc score of 3 and the anticoagulation treatment was continued. This patient had a CHA2DS2-VASc score of 3, and HAS-BLED score of 1. Considering the uncompelling benefits of anticoagulation therapy in this particular patient, we chose to treat the patient with ASA monotherapy assuming that the spontaneously occluded LAA would prevent thromboembolic complications similar to a transcatheter LAAO and in order to keep the bleeding risk low.
Lead author biography

Andreas Bugge Tinggaard is a junior doctor at the Department of Cardiology, Aarhus University Hospital, Denmark. His field of interest includes atrial fibrillation, anticoagulation therapy, left atrial appendage occlusion, and stroke prevention.

Supplementary material

Supplementary material is available at European Heart Journal - Case Reports online.

Acknowledgements

The authors want to give an honourable mention to Professor Grethe Andersen, DMSc, from Department of Neurology, Aarhus University Hospital, for her contribution to this case.

Figure 1 Baseline imaging showing no left atrial appendage (arrows). (A–C) Computed tomography scans, (D) three-dimensional computed tomography rendering, (E) transoesophageal echocardiography, and (F) three-dimensional transoesophageal echocardiography.

Slide sets: A fully edited slide set detailing this case and suitable for local presentation is available online as Supplementary data.

Consent: A verbal consent has been obtained from the patient prior to any work up regarding this article and prior to submission. By Danish law, this is required to access any of the patient’s data in the electronic medical record and to use it for scientific and educational purposes. The consent has been documented in the electronic medical record.

Conflict of interest: none declared.

References

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–988.
2. Reddy VY, Doshi SK, Kar S, Gibson DN, Price MJ, Huber K, Horton RP, Buchbinder M, Neuzil P, Gordon NT, Holmes DR. 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol. 2017;70:2964–2975.
3. Hart RG, Diener H-C, Coutts SB, Easton JD, Granger CB, O’Donnell MJ, Sacco RL, Connolly SJ. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014;13:429–438.
4. Hart RG, Sharma M, Mundl H, Kasner SE, Bangdolsa SI, Berkowitz SD, Swaminathan B, Lavados P, Wang Y, Wang Y, Davalos A, Shalek M, Mikulik R, Cunha L, Lindgren A, Arauz A, Lang W, Czlonkowska A, Eckstein J, Gagliardi RJ, Amarenco P, Ameriso SF, Tatsisumak T, Veliskamp R, Hankey GJ, Toni D, Bereczki D, Uchiyama S, Ntaios G, Yoon B-W, Bruns R, Endres M, Muir KW, Bornstein N, Oztsurk S, O’Donnell MJ, De Vries Basson MM, Pare G, Pater C.
Kirsch B, Sheridan P, Peters G, Weitz JI, Peacock WF, Shoamanesh A, Benavente OR, Joyner C, Themeles E, Connolly SJ. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 2018;378:2191–2201.

5. Di Gioia G, Mega S, Vasconi S, Campanale CM, Creta A, Ragni L, Di Sciascio G. Congenital absence of left atrial appendage in a patient with intracranial hemorrhage. Am J Case Rep 2015;16:514–516.

6. Dar T, Yarlagadda B, Swarup V, Lakkireddy D. Congenital absence of left atrial appendage. J Atr Fibrillation 2017;10:1730.

7. Collier P, Cavalcante JL, Phelan D, Thavendranathan P, Dahiya A, Grant A, Kwon D, Thamilarasan M. Congenital absence of the left atrial appendage. Circ Cardiovasc Imaging 2012;5:549–550.

8. Enomoto Y, Hashimoto G, Sahara N, Hashimoto H, Niikura H, Nakamura K, Iijima R, Hara H, Suzuki M, Noro M, Moroi M, Sugi K, Nakamura M. Congenital absence of left atrial appendage diagnosed by multimodality imaging. Int Heart J 2018;59:439–442.

9. Ghori MA, Alessandro S. Congenital absence of left atrial appendage: a case report and literature review. J Saudi Heart Assoc 2015;27:132–134.

10. Vira T, Pechlivanoglou P, Connelly K, Wijeyasurya HC, Rofman I. Cardiac computed tomography and magnetic resonance imaging vs. transoesophageal echocardiography for diagnosing left atrial appendage thrombi. Europace 2019;21:ef1–ef10.

11. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, Fang MC, Fisher M, Furie KL, Heck DV, Johnston SC, Kasner SE, Kittner SJ, Mitchell PH, Rich MW, Richardson D, Schwamm LH, Wilson JA. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014;45:2160–2236.

12. Palus SH, Hansen AT, Hvas AM. Thrombophilia testing in young patients with ischemic stroke. Thromb Res 2016;137:108–112.

13. Al-Saady NM, Obel OA, Camm AJ. Left atrial appendage: structure, function, and role in thromboembolism. Heart 1999;82:547–554.

14. Cresti A, Garcia-Fernández MA, Sievert H, Mazzone P, Baratta P, Solari M, Geyer A, De Sensi F, Limbruno U. Prevalence of extra-appendage thrombosis in non-valvular atrial fibrillation and atrial flutter in patients undergoing cardioversion: a large transoesophageal echo study. Eurointervention 2019;15:e225–e230.

15. Whang W, Holmes DR, Miller MA, Langan M-N, Choudry S, Sofi A, Koruth JS, Dulkipari SR, Reddy VY. Does left atrial appendage closure reduce mortality? A vital status analysis of the randomized PROTECT AF and PREVAIL clinical trials. J Atr Fibrillation 2018;11:2119.

16. Diener H-C, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchigaya S, Kreuzer J, Cronin L, Cotton D, Grauer C, Brueckmann M, Chernyatsina M, Donnan G, Ferro JM, Grund M, Kallmünzer B, Krupinski J, Lee B-C, Lemmens R, Masjuan J, Oidnak M, Saver J, Schelling PD, Toni D, Toyoda K, Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med 2019;380:1906–1917.

17. Nandar PP, Kichloo A, Aung TT, Kravitz KD. Therapeutic dilemma of natural watchman: congenital absence of the left atrial appendage. Case Rep Cardiol 2018;2018:7573425.

18. Korsholm K, Nielsen KM, Jensen JM, Jensen HK, Andersen G, Nielsen-Kudsk JE. Transcatheter left atrial appendage occlusion in patients with atrial fibrillation and a high bleeding risk using aspirin alone for post-implant antithrombotic therapy. Eurointervention 2017;12:2075–2082.

Figure 2. A follow-up imaging showing stationary results. (A and B) Six-month computed tomography scan, (C and D) 12-month computed tomography scan, (E) 12-month transoesophageal echocardiography, and (F) 12-month three-dimensional transoesophageal echocardiography.